Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator

The safety, efficacy, and cost-effectiveness of Infliximab biosimilar agents in the management of inflammatory bowel disease in adults have been shown. These agents have been recommended for pediatric inflammatory bowel disease, and although institutions are initiating therapy with the biosimilar ag...

Descripción completa

Detalles Bibliográficos
Autores principales: Hinshaw, Amie, Cares, Kristen, Thomas, Ron, El-Baba, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins, Inc. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158373/
https://www.ncbi.nlm.nih.gov/pubmed/37168460
http://dx.doi.org/10.1097/PG9.0000000000000256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158373/
https://www.ncbi.nlm.nih.gov/pubmed/37168460
http://dx.doi.org/10.1097/PG9.0000000000000256

Ejemplares similares